

ASX Code: MYQ

ABN 85 602 111 115

Corporate Structure

Issued Capital: ~114M

Options Issued: ~11.45M

Perform Rights: ~15.75M

Share price: \$0.285 (29 Jul '20)

CORPORATE DIRECTORY

Non-Executive Directors

Peter Wall (Chairman)

Mike Melby

Nick Prosser

Chief Executive Officer

Vlado Bosanac

Company Secretary

& Chief Financial Officer

Steven Richards

CONTACT DETAILS

Unit 5, 71-73 South Perth

Esplanade, South Perth, WA
6151

PO Box 190

South Perth, WA 6951

E: admin@myfiziq.com

myfiziq.com

MyFiziq achieves its best quarterly to date in challenging conditions

MyFiziq Limited (ASX: MYQ) (MyFiziq or Company) is pleased to release its Appendix 4C and to provide its shareholders with an update on its activities for the quarter ending 30 June 2020.

HIGHLIGHTS

- MyFiziq generated \$93k in net cash from operating activities and a further \$462k in net cash from financing activities, to achieve its best quarterly result since December 2017.
- Cash expenditure reduces from an average of \$1.189 million per quarter over the past three (3) quarters, to \$586k in the current quarter, representing a 49% decrease in spend.
- Cash inflows of \$1.666 million during the current quarter allow the Company to repay \$550k in borrowings, with a further \$1.34 million in convertible note debt settled (by way of a share issue).
- In July 2020, the Company received a further \$450k in payments from partners as well as the tranche 3 payment of USD\$450,000 (under the convertible note subscription deed announced with Asia Cornerstone Asset Management).
- The Company has further expected inflows of funds from Asia Cornerstone Asset Management ("ACAM") (USD\$375k), balance of licence payments (\$300k) and development payments (\$120k),
- The above has been achieved despite the challenging economic conditions brought about by COVID-19, with further go-lives expected over the next quarter as the Company gears for growth.

Vlado Bosanac, Chief Executive Officer of MyFiziq said:

"What should have been the Company's most challenging quarter due to the current pandemic and reductions in spending rife in all business communities, was in fact one of the Company's best quarters to date. MyFiziq shone on many levels, with the commencement of the process to enter the NASDAQ, substantial reduction in debt, increase in business activity with Evolt going live, signing of new commercial agreements, partner revenue and license fee payments.

We closed out the quarter with the support of our major investor, ACAM, agreeing to a new funding package to strengthen the Company's balance sheet in advance of its US foray. In addition to this, we commenced the build of CompleteHealth (in collaboration with NuraLogix), which has attracted interest from 25 companies wanting to add facial scanning to their product offering.

The work ethic of our team has been exemplary as they focus on application delivery and cost reductions, allowing me to focus on new partner engagement and our NASDAQ initiative.



This coming quarter we will continue to drive the signing of new partnerships whilst the team focuses on delivery timeframes being shortened. We are in a critical phase now of rollout to revenue. We will remain focused and we will look to share more positive news as we progress both commercially and financially.”

IMPACT OF COVID-19

As mentioned in the Shareholder Update dated 29 June 2020, MyFiziq has remained on task and accelerated integrations notwithstanding the global pandemic which is affecting so many organizations and financial markets. The positive cash flow result produced for this current quarter provides evidence that Company has been able to withstand the financial pressures of COVID-19, whilst at the same time gearing itself for further growth.

UPDATE ON PRODUCT LAUNCHES

The Evolt application was launched on the Apple App store following a phased implementation, to a small initial target audience, with further incremental increases over the month. The benefit of such an approach is that it allows our partner (Evolt) to attend to any issues prior to a larger marketing push. This emerged as the right approach with 2 disruptions to the service, slowing the release. Importantly, the disruption was not on the MyFiziq side of the solution and has been handled by the Evolt team with urgency and competence.

At this point, we anticipate that Evolt will launch its marketing campaign by the middle of August 2020, and we will be in a better position by the end of September 2020 to gauge the initial subscription numbers.

Next quarter Planned Activity:

Our developers are currently engaged in final testing and implementation of both the Bearn and Boditrax apps, which are expected to be launched in early and late August 2020.

CompleteHealth with NuraLogix:

The implementation is well underway and drawing substantial attention from partners. Current engaged partners both new and old has risen to 25 in total. The combined offering is unique and compelling, and we are looking forward to updating our shareholders as we complete the application for phase 1 testing and release.

CASHFLOW UPDATE

The Company has had its best quarter since December 2017, generating net cash from both operating (\$93k) and financing activities (\$462k), with a nominal amount of net cash used in investing activities (\$19k), as follows:

Cash flow from operations:

The Company generated positive cash from operating activities of \$93k, which effectively demonstrates that there was zero ‘cash burn’ for the current quarter. This a significant milestone for the Company, given the harsh trading reality facing businesses today.

As Table 1 below suggests, the Company received \$654k from customers and partners during the June 2020 quarter. This is a pleasing result for the Company given the challenges faced with negotiating with suppliers and collecting money in the current economic climate. When comparing the June 2020 quarter to the three (3) previous quarters, it is evident the Company has managed to generate significantly more cash from operating activities, as well as tighten up on expenditure by materially reducing discretionary spending, while at the same time being alert to the various government grants on offer.

Regarding expenditure, the average operating cash expenditure for the prior 3 quarters, is \$1,189k (which is the average of \$1,182k and \$1,332k and \$1,054k), whilst the operating cash expenditure for June 2020 is \$586k, this represents a 49% reduction in expenses for the quarter.

	September '19 QTR \$'000	December '19 QTR \$'000	March '20 QTR \$ '000	June '20 QTR \$ '000	Change on previous QTR (June '20 vs March '20) \$ '000
Cash received from operations	38	42	32	654	622 improvement
Operating cash expenditure	(1,182)	(1,332)	(1,054)	(586)	468 improvement
Grants and tax refunds	-	666	-	50	50 improvement
Interest paid	(1)	(1)	(1)	(25)	-24 (additional interest paid on debt)
Net cash from (used in) operating activities	(1,145)	(625)	(1,023)	93	1,116 improvement

Table 1. Cash flow summary by quarter

As Figure 1 illustrates, the Company has managed to increase its cash received from operating activities by \$622k whilst decreasing its operating cash expenditure by \$468k, which has contributed to a productive June 2020 quarter, as is reflected in the Appendix 4C for June 2020 (attached):




Figure 1. Cash receipts and cash payments trendline

Cash flow from financing activities:

In addition to the significant improvement made to the operating results, the Company has also managed to secure USD\$1.5million in funding from Asia Cornerstone Asset Management (“ACAM”) by way of convertible note (as announced on 1 June 2020).

During the current quarter, \$322k of the above ACAM funding had been received, together with a \$600k advance received from R&D Capital Partners Pty Ltd (“R&D”). This loan provides for an advance of up to 80% of the Company’s anticipated 2020 R&D tax rebate. The Company also received \$90k in short-term borrowings (which has since been repaid) which means \$1.012 million in cash from financing activities was received during the current quarter.

Under the terms of the funding agreement, ACAM has agreed to fund the Company over 4 tranches. At the date of this announcement, USD\$1.125 million had been received with the balance of USD\$375k expected to be received in August 2020. Further information regarding the above funding arrangement can be found under Item 7.6 of the attached Appendix 4C.

Use of funds:

During the current quarter, a total of \$1.666 million in funds had been received from a combination of operating activities, ACAM and R&D. The steady build-up of cash flow reserves has put the Company in a position to repay \$550k in borrowings, with a further \$1.34 million in convertible note debt was settled by way of a share issue on 30 June 2020 (as announced on 18 June 2020). This brings the total reduction in debt during the quarter to \$1.89 million, which allowed the Company to close off the year with a significantly improved balance sheet.

Further improvements post-June 2020:

In July 2020, the Company received \$250k from partner and development payments for works carried out on partner builds and integrations as well as a license fee instalment of \$200,000, which forms a part-payment toward the balance of the \$500,000 license fee owing to MyFiziq under the joint venture agreement with BCT. In addition, the Company received the tranche 3 payment of USD\$450,000 under the convertible note subscription deed announced with ACAM, which has been referred to above and listed under Item 7.6 of the attached Appendix 4C for the June 2020 Quarter.

The receipt of the above funds during the post-June 2020 period has put the Company in the position to settle a further \$140,000 in borrowings also enabled MyFiziq to participate in a funding round with BCT, which resulted in MyFiziq taking the majority stake in Body Composition Technologies Pte Limited by investing \$670,833 by way of convertible note (as announced on 20 July 2020). All the above-mentioned post-June 2020 transactions combine to further strengthen the assets of the Company, whilst reducing debt.

Steven Richards, Chief Financial Officer of MyFiziq said:

“In a pandemic world, the Company has shown unyielding stability by producing a substantial cash flow result for the quarter. It is the first time since December 2017 that the Company has generated positive cashflow from operating activities.

Overall, we received \$1.666 million in cash inflows during the quarter and, at 30 June 2020, we had a \$1.848 million in available cash courtesy of partner payments and funding that was received from Asia Cornerstone Asset Management in June 2020. We have also reduced our operating cash expenditure by 49%, when compared to the average of the previous three (3) months.

Having raised funds, collected monies owed and tightened the lockdown expenditure, we put ourselves in a position to reduce Company debt with the repayment of \$550k in borrowings by year-end. Our financial position improved further when convertible note holders elected to convert their notes during the quarter,



effectively reducing the Company's liabilities by an additional \$1.337 million. This represents a considerable vote of confidence in the Company and team.

* - all currency in AUD, unless stated otherwise

RELATED PARTY TRANSACTIONS

During the quarter, the Company made the following payments under Item 1 of the attached Appendix 4C:

Directors fees, under a contract for services:	\$26k
Legal fees paid to Steinepreis Paganin:	<u>\$1k</u>
Total related party payments:	\$27k

No related party payments have been made under Item 2 of the attached Appendix 4C.

Forward-Looking Statements

This document may include forward-looking statements. Forward-looking statements include, but are not limited to, statements concerning MyFiziq Limited's planned partner integrations, forecast partner revenue, and other statements that are not historical facts. When used in this document, the words such as "could," "plan", "estimate," "expect," "intend," "may", "potential", "should," and similar expressions are forward-looking statements. Although MyFiziq Limited believes that its expectations reflected in these forward-looking statements are reasonable, such statements involve risks and uncertainties and no assurance can be given that actual results will be consistent with these forward-looking statements.

About MyFiziq:

MyFiziq has developed and patented a proprietary dimensioning technology that enables its users to check, track, and assess their dimension using only a smartphone privately and accurately.

Our goal is to assist our partners by empowering their consumers with this capability. This in return gives our partners the ability to assess, assist, and communicate outcomes with their consumers when navigating day to day life. Whether this is a personal journey to better health, understanding the risk associated with their physical condition, tracking the changes they are experiencing through training, dieting, or under medical regimes. or simply wanting to be correctly sized for a garment when shopping online. The MyFiziq technology delivers this seamlessly, privately, and cost-effectively in under one minute.

Our partner benefits from our (SAAS) Software as a service pricing solution, that reduces with scale. Integration is made easy with the MyFiziq modular system, based on multiple (SDK's) software development kits, allowing a partner to select the functions, measurements, and displays to suit their individual needs.

MyFiziq has developed this capability by leveraging the power of Computer Vision, Machine Learning, and patented algorithms, to process these images on secure, enterprise-level infrastructure, delivering an end-to-end experience that is unrivaled in the industry. MyFiziq simplifies the collection of measurements and removes the human error present in traditional methods.

This announcement has been approved for release by the board of directors of MyFiziq Limited.

For more information please visit: www.myfiziq.com

For more information contact:

Vlado Bosanac,
Chief Executive Officer
MyFiziq Limited
E: admin@myfiziq.com

Steven Richards,
Chief Financial Officer
MyFiziq Limited
E: admin@myfiziq.com

ASX Code: MYQ

ABN 85 602 111 115

Corporate Structure

Issued Capital: ~114M

Options Issued: ~11.45M

Perform Rights: ~15.75M

Share price: \$0.275 (28 Jul '20)

CORPORATE DIRECTORY

Non-Executive Directors

Peter Wall (Chairman)

Mike Melby

Nick Prosser

Chief Executive Officer

Vlado Bosanac

Company Secretary

& Chief Financial Officer

Steven Richards

CONTACT DETAILS

Unit 5, 71-73 South Perth

Esplanade, South Perth, WA
6151

PO Box 190

South Perth, WA 6951

E: admin@myfiziq.com

myfiziq.com

MyFiziq achieves its best quarterly to date in challenging conditions

MyFiziq Limited (ASX: MYQ) (MyFiziq or Company) is pleased to release its Appendix 4C and to provide its shareholders with an update on its activities for the quarter ending 30 June 2020.

HIGHLIGHTS

- MyFiziq generated \$93k in net cash from operating activities and a further \$462k in net cash from financing activities, to achieve its best quarterly result since December 2017.
- Cash expenditure reduces from an average of \$1.189 million per quarter over the past three (3) quarters, to \$586k in the current quarter, representing a 49% decrease in spend.
- Cash inflows of \$1.666 million during the current quarter allow the Company to repay \$550k in borrowings, with a further \$1.34 million in convertible note debt settled (by way of a share issue).
- In July 2020, the Company received a further \$450k in payments from partners as well as the tranche 3 payment of USD\$450,000 (under the convertible note subscription deed announced with Asia Cornerstone Asset Management).
- The Company has further expected inflows of funds from Asia Cornerstone Asset Management ("ACAM") (USD\$375k), balance of licence payments (\$300k) and development payments (\$120k),
- The above has been achieved despite the challenging economic conditions brought about by COVID-19, with further go-lives expected over the next quarter as the Company gears for growth.

Vlado Bosanac, Chief Executive Officer of MyFiziq said:

"What should have been the Company's most challenging quarter due to the current pandemic and reductions in spending rife in all business communities, was in fact one of the Company's best quarters to date. MyFiziq shone on many levels, with the commencement of the process to enter the NASDAQ, substantial reduction in debt, increase in business activity with Evolt going live, signing of new commercial agreements, partner revenue and license fee payments.

We closed out the quarter with the support of our major investor, ACAM, agreeing to a new funding package to strengthen the Company's balance sheet in advance of its US foray. In addition to this, we commenced the build of CompleteHealth (in collaboration with NuraLogix), which has attracted interest from 25 companies wanting to add facial scanning to their product offering.

The work ethic of our team has been exemplary as they focus on application delivery and cost reductions, allowing me to focus on new partner engagement and our NASDAQ initiative.



This coming quarter we will continue to drive the signing of new partnerships whilst the team focuses on delivery timeframes being shortened. We are in a critical phase now of rollout to revenue. We will remain focused and we will look to share more positive news as we progress both commercially and financially.”

IMPACT OF COVID-19

As mentioned in the Shareholder Update dated 29 June 2020, MyFiziq has remained on task and accelerated integrations notwithstanding the global pandemic which is affecting so many organizations and financial markets. The positive cash flow result produced for this current quarter provides evidence that Company has been able to withstand the financial pressures of COVID-19, whilst at the same time gearing itself for further growth.

UPDATE ON PRODUCT LAUNCHES

The Evolt application was launched on the Apple App store following a phased implementation, to a small initial target audience, with further incremental increases over the month. The benefit of such an approach is that it allows our partner (Evolt) to attend to any issues prior to a larger marketing push. This emerged as the right approach with 2 disruptions to the service, slowing the release. Importantly, the disruption was not on the MyFiziq side of the solution and has been handled by the Evolt team with urgency and competence.

At this point, we anticipate that Evolt will launch its marketing campaign by the middle of August 2020, and we will be in a better position by the end of September 2020 to gauge the initial subscription numbers.

Next quarter Planned Activity:

Our developers are currently engaged in final testing and implementation of both the Bearn and Boditrax apps, which are expected to be launched in early and late August 2020.

CompleteHealth with NuraLogix:

The implementation is well underway and drawing substantial attention from partners. Current engaged partners both new and old has risen to 25 in total. The combined offering is unique and compelling, and we are looking forward to updating our shareholders as we complete the application for phase 1 testing and release.

CASHFLOW UPDATE

The Company has had its best quarter since December 2017, generating net cash from both operating (\$93k) and financing activities (\$462k), with a nominal amount of net cash used in investing activities (\$19k), as follows:

Cash flow from operations:

The Company generated positive cash from operating activities of \$93k, which effectively demonstrates that there was zero ‘cash burn’ for the current quarter. This a significant milestone for the Company, given the harsh trading reality facing businesses today.

As Table 1 below suggests, the Company received \$654k from customers and partners during the June 2020 quarter. This is a pleasing result for the Company given the challenges faced with negotiating with suppliers and collecting money in the current economic climate. When comparing the June 2020 quarter to the three (3) previous quarters, it is evident the Company has managed to generate significantly more cash from operating activities, as well as tighten up on expenditure by materially reducing discretionary spending, while at the same time being alert to the various government grants on offer.

Regarding expenditure, the average operating cash expenditure for the prior 3 quarters, is \$1,189k (which is the average of \$1,182k and \$1,332k and \$1,054k), whilst the operating cash expenditure for June 2020 is \$586k, this represents a 49% reduction in expenses for the quarter.

	September '19 QTR	December '19 QTR	March '20 QTR	June '20 QTR	Change on previous QTR (June '20 vs March '20)
	\$'000	\$'000	\$ '000	\$ '000	\$ '000
Cash received from operations	38	42	32	654	622 improvement
Operating cash expenditure	(1,182)	(1,332)	(1,054)	(586)	468 improvement
Grants and tax refunds	-	666	-	50	50 improvement
Interest paid	(1)	(1)	(1)	(25)	-24 (additional interest paid on debt)
Net cash from (used in) operating activities	(1,145)	(625)	(1,023)	93	1,116 improvement

Table 1. Cash flow summary by quarter

As Figure 1 illustrates, the Company has managed to increase its cash received from operating activities by \$622k whilst decreasing its operating cash expenditure by \$468k, which has contributed to a productive June 2020 quarter, as is reflected in the Appendix 4C for June 2020 (attached):




Figure 1. Cash receipts and cash payments trendline

Cash flow from financing activities:

In addition to the significant improvement made to the operating results, the Company has also managed to secure USD\$1.5million in funding from Asia Cornerstone Asset Management (“ACAM”) by way of convertible note (as announced on 1 June 2020).

During the current quarter, \$322k of the above ACAM funding had been received, together with a \$600k advance received from R&D Capital Partners Pty Ltd (“R&D”). This loan provides for an advance of up to 80% of the Company’s anticipated 2020 R&D tax rebate. The Company also received \$90k in short-term borrowings (which has since been repaid) which means \$1.012 million in cash from financing activities was received during the current quarter.

Under the terms of the funding agreement, ACAM has agreed to fund the Company over 4 tranches. At the date of this announcement, USD\$1.125 million had been received with the balance of USD\$375k expected to be received in August 2020. Further information regarding the above funding arrangement can be found under Item 7.6 of the attached Appendix 4C.

Use of funds:

During the current quarter, a total of \$1.666 million in funds had been received from a combination of operating activities, ACAM and R&D. The steady build-up of cash flow reserves has put the Company in a position to repay \$550k in borrowings, with a further \$1.34 million in convertible note debt was settled by way of a share issue on 30 June 2020 (as announced on 18 June 2020). This brings the total reduction in debt during the quarter to \$1.89 million, which allowed the Company to close off the year with a significantly improved balance sheet.

Further improvements post-June 2020:

In July 2020, the Company received \$250k from partner and development payments for works carried out on partner builds and integrations as well as a license fee instalment of \$200,000, which forms a part-payment toward the balance of the \$500,000 license fee owing to MyFiziq under the joint venture agreement with BCT. In addition, the Company received the tranche 3 payment of USD\$450,000 under the convertible note subscription deed announced with ACAM, which has been referred to above and listed under Item 7.6 of the attached Appendix 4C for the June 2020 Quarter.

The receipt of the above funds during the post-June 2020 period has put the Company in the position to settle a further \$140,000 in borrowings also enabled MyFiziq to participate in a funding round with BCT, which resulted in MyFiziq taking the majority stake in Body Composition Technologies Pte Limited by investing \$670,833 by way of convertible note (as announced on 20 July 2020). All the above-mentioned post-June 2020 transactions combine to further strengthen the assets of the Company, whilst reducing debt.

Steven Richards, Chief Financial Officer of MyFiziq said:

“In a pandemic world, the Company has shown unyielding stability by producing a substantial cash flow result for the quarter. It is the first time since December 2017 that the Company has generated positive cashflow from operating activities.

Overall, we received \$1.666 million in cash inflows during the quarter and, at 30 June 2020, we had a \$1.848 million in available cash courtesy of partner payments and funding that was received from Asia Cornerstone Asset Management in June 2020. We have also reduced our operating cash expenditure by 49%, when compared to the average of the previous three (3) months.

Having raised funds, collected monies owed and tightened the lockdown expenditure, we put ourselves in a position to reduce Company debt with the repayment of \$550k in borrowings by year-end. Our financial position improved further when convertible note holders elected to convert their notes during the quarter,



effectively reducing the Company's liabilities by an additional \$1.337 million. This represents a considerable vote of confidence in the Company and team.

* - all currency in AUD, unless stated otherwise

RELATED PARTY TRANSACTIONS

During the quarter, the Company made the following payments under Item 1 of the attached Appendix 4C:

Directors fees, under a contract for services:	\$26k
Legal fees paid to Steinepreis Paganin:	<u>\$1k</u>
Total related party payments:	\$27k

No related party payments have been made under Item 2 of the attached Appendix 4C.

Forward-Looking Statements

This document may include forward-looking statements. Forward-looking statements include, but are not limited to, statements concerning MyFiziq Limited's planned partner integrations, forecast partner revenue, and other statements that are not historical facts. When used in this document, the words such as "could," "plan", "estimate," "expect," "intend," "may", "potential", "should," and similar expressions are forward-looking statements. Although MyFiziq Limited believes that its expectations reflected in these forward-looking statements are reasonable, such statements involve risks and uncertainties and no assurance can be given that actual results will be consistent with these forward-looking statements.

About MyFiziq:

MyFiziq has developed and patented a proprietary dimensioning technology that enables its users to check, track, and assess their dimension using only a smartphone privately and accurately.

Our goal is to assist our partners by empowering their consumers with this capability. This in return gives our partners the ability to assess, assist, and communicate outcomes with their consumers when navigating day to day life. Whether this is a personal journey to better health, understanding the risk associated with their physical condition, tracking the changes they are experiencing through training, dieting, or under medical regimes. or simply wanting to be correctly sized for a garment when shopping online. The MyFiziq technology delivers this seamlessly, privately, and cost-effectively in under one minute.

Our partner benefits from our (SAAS) Software as a service pricing solution, that reduces with scale. Integration is made easy with the MyFiziq modular system, based on multiple (SDK's) software development kits, allowing a partner to select the functions, measurements, and displays to suit their individual needs.

MyFiziq has developed this capability by leveraging the power of Computer Vision, Machine Learning, and patented algorithms, to process these images on secure, enterprise-level infrastructure, delivering an end-to-end experience that is unrivaled in the industry. MyFiziq simplifies the collection of measurements and removes the human error present in traditional methods.

This announcement has been approved for release by the board of directors of MyFiziq Limited.

For more information please visit: www.myfiziq.com

For more information contact:

Vlado Bosanac,
Chief Executive Officer
MyFiziq Limited
E: admin@myfiziq.com

Steven Richards,
Chief Financial Officer
MyFiziq Limited
E: admin@myfiziq.com

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

MyFiziq Limited

ABN

85 602 111 115

Quarter ended ("current quarter")

30 June 2020

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (12 months) \$A'000
1. Cash flows from operating activities		
1.1 Receipts from customers	654	848
1.2 Payments for		
(a) research and development	-	-
(b) product manufacturing and operating costs	-	-
(c) advertising and marketing	(1)	(34)
(d) leased assets	-	-
(e) staff costs	(465)	(2,639)
(f) administration and corporate costs	(120)	(1,481)
1.3 Dividends received (see note 3)	-	-
1.4 Interest received	-	-
1.5 Interest and other costs of finance paid	(25)	(28)
1.6 Income taxes paid	-	-
1.7 Government grants and tax incentives	50	716
1.8 Other (provide details if material)		
1.9 Net cash from / (used in) operating activities	93	(2,618)
2. Cash flows from investing activities		
2.1 Payments to acquire or for:		
(a) entities	-	-
(b) businesses	-	-
(c) property, plant and equipment	-	(62)
(d) investments	-	-
(e) intellectual property	(19)	(104)
(f) other non-current assets	-	-

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (12 months) \$A'000
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	Net cash from / (used in) investing activities	(19)	(166)

3.	Cash flows from financing activities		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	-	2,050
3.2	Proceeds from issue of convertible debt securities	322	322
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	-	(122)
3.5	Proceeds from borrowings	690	790
3.6	Repayment of borrowings	(550)	(200)
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (provide details if material)	-	-
3.10	Net cash from / (used in) financing activities	462	2,840

4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of period	94	574
4.2	Net cash from / (used in) operating activities (item 1.9 above)	93	(2,618)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(19)	(166)

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (12 months) \$A'000
4.4	Net cash from / (used in) financing activities (item 3.10 above)	462	2,840
4.5	Effect of movement in exchange rates on cash held	-	-
4.6	Cash and cash equivalents at end of period	630	630

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	630	94
5.2	Call deposits	-	-
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	630	94

6.	Payments to related parties of the entity and their associates	Current quarter \$A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	27
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-
<i>Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.</i>		

7.	Financing facilities <i>Note: the term "facility" includes all forms of financing arrangements available to the entity.</i> <i>Add notes as necessary for an understanding of the sources of finance available to the entity.</i>	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
7.1	Loan facilities	600	600
7.2	Credit standby arrangements	-	-
7.3	Other - Convertible note: Asia Cornerstone Asset Management	2,174	326
7.4	Total financing facilities	2,774	926
7.5	Unused financing facilities available at quarter end		1,848
7.6	<p>Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.</p> <div style="border: 1px solid black; padding: 10px;"> <p><u>7.1 LOAN FACILITIES</u></p> <p>Facility amount: \$600,000</p> <p>Lender: R&D Capital Partners Pty Ltd, for an advance of up to 80% of the Company's anticipated 2020 R&D tax rebate.</p> <p>Term: No principal payments are to be made until the repayment date, being the earlier of:</p> <ul style="list-style-type: none"> - the Borrower receiving its 2020 tax refund from the ATO. - or 31 October 2020. <p>Interest rate: 1.5% per month</p> <p>Establishment fee: \$4,500</p> <p>Primary security interest: Secured by a lien on the Company's 2020 R&D tax refund.</p> <p><u>7.3 OTHER – CONVERTIBLE NOTE: ASIA CORNERSTONE ASSET MANAGEMENT</u></p> <p>Funding amount: USD\$1.5 million or AUD\$2.17 million, in four (4) separate tranches* (outline below)</p> <p>Interest rate: 10% per annum</p> <p>Other terms:</p> <ul style="list-style-type: none"> • The funding has a mandatory conversion upon a successful NASDAQ listing. • On conversion, ACAM will be issued shares in the NASDAQ listed company at the greater of US\$1.00 and a 25% discount to the price at which the Company issues shares in conjunction with the listing. • In the event MyFiziq is not successful in attaining a listing on the NASDAQ on or prior to 30 June 2021, MyFiziq will have an additional 6 months to repay the capital. • The note is not secured. <p><u>*Tranches</u></p> <ul style="list-style-type: none"> • Tranche 1 USD\$225,000 – Received June 2020 (current quarter). • Tranche 2 USD\$450,000 – Received July 2020 (following quarter). • Tranche 3 USD\$450,000 – Received July 2020 (following quarter). • Tranche 4 USD\$375,000 -14 days from the date that the Company engages an underwriter or an investment bank to provide services in connection with the NASDAQ Listing. </div>		

8.	Estimated cash available for future operating activities	\$A'000
8.1	Net cash from / (used in) operating activities (item 1.9)	93
8.2	Cash and cash equivalents at quarter end (item 4.6)	630
8.3	Unused finance facilities available at quarter end (item 7.5)	1,848
8.4	Total available funding (item 8.2 + item 8.3)	2,478
8.5	Estimated quarters of funding available (item 8.4 divided by item 8.1) <i>Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.</i>	N/A – the Company has reported positive net operating cash outflows
8.6	If item 8.5 is less than 2 quarters, please provide answers to the following questions: 8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not? <div style="border: 1px solid black; padding: 5px; margin: 5px 0;">Answer: N/a</div> 8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful? <div style="border: 1px solid black; padding: 5px; margin: 5px 0;">Answer: N/a</div> 8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis? <div style="border: 1px solid black; padding: 5px; margin: 5px 0;">Answer: N/a</div> <i>Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.</i>	

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date:30 June 2020.....

Authorised by:By Order of the Board.....
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An

entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.

2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.